Sanofi synthesizes new ERK5 inhibitors
Several Sanofi SA patents divulge new mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors potentially useful for the treatment of cancer.
Several Sanofi SA patents divulge new mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors potentially useful for the treatment of cancer.
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.